Porvair Sciences reports on increased demand for the 3D moulded intake filters and vent diffusers it supplies to GCE Healthcare - manufacturer of the Zen-O lite™ Portable Oxygen Concentrator. Zen-O lite™ Portable Oxygen Concentrators
Zen-O lite™ is an ultra-lightweight portable oxygen concentrator from GCE Healthcare ( www.gcehealthcare.com ) that weighs just 2.5 kg (5.5 lbs). The device is designed for active people suffering from respiratory conditions such as COPD (Chronic Obstructive Pulmonary Disease) that require long term oxygen therapy. With its advanced breath detection technology, the Zen-O lite automatically responds to breathing rate and will adjust to a person’s specific needs to ensure that their lungs are receiving effective oxygen saturation.
Governments worldwide are calling upon engineering and healthcare companies to help patients infected by COVID-19 to increase output of respiratory assistance devices. In response to this call for humanitarian aid - Porvair Sciences has prioritised manufacturing capacity to enable us to respond quickly to GCE Healthcare's urgent request for quick turnaround on the critical Vyon ® porous plastic filters we supply for their Zen-O lite™ device.
The air intake filter we supply for the Zen-O lite™ device eliminates blockages and ensures that there is a flow of oxygen to the required specifications. Vyon ® porous plastics provide an ideal material for gas filtration as their tortuous path ensures excellent depth filtration. As specialists in porous plastics we have the knowledge, experience and manufacturing capacity to quickly produce components in a variety of pore sizes and thickness enabling filtration of a large range of different particulate. Our materials are also effective at bacterial filtration and preventing microbial ingress". Alan Hughes, Porous Plastics Accounts Manager for Porvair Sciences Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology